
Sotera Health Company SHC
$ 15.27
-1.42%
Quarterly report 2026-Q1
added 05-05-2026
Sotera Health Company Book Value 2011-2026 | SHC
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Sotera Health Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 606 M | 405 M | 444 M | 350 M | 586 M | 455 M | -641 M | 45.5 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 606 M | -641 M | 281 M |
Quarterly Book Value Sotera Health Company
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 623 M | 550 M | 511 M | 414 M | 470 M | 423 M | 429 M | 377 M | 418 M | 361 M | 350 M | 607 M | - | 642 M | 586 M | 526 M | 523 M | 466 M | 455 M | 455 M | 455 M | 455 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 642 M | 350 M | 481 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Co-Diagnostics
CODX
|
20.6 M | $ 1.29 | -21.17 % | $ 1.72 M | ||
|
Agilent Technologies
A
|
5.39 B | $ 111.7 | -1.36 % | $ 34 B | ||
|
Castle Biosciences
CSTL
|
471 M | $ 19.13 | 1.32 % | $ 555 M | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 15.7 | -3.03 % | $ 475 M | ||
|
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
6.3 B | $ 142.54 | -0.49 % | $ 22.7 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
22.4 M | $ 1.76 | -2.22 % | $ 7.79 M | ||
|
CareDx, Inc
CDNA
|
303 M | $ 19.97 | -2.54 % | $ 1.06 B | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
7.49 M | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 93.91 | -2.86 % | $ 6.34 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
459 M | $ 415.27 | -0.93 % | $ 12 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 031.64 | -0.99 % | $ 21.3 B | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Myriad Genetics
MYGN
|
368 M | $ 3.58 | -1.1 % | $ 332 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
NeoGenomics
NEO
|
837 M | $ 8.24 | -1.44 % | $ 1.06 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
14 M | $ 18.62 | -1.64 % | $ 417 M | ||
|
Charles River Laboratories International
CRL
|
3.21 B | $ 150.85 | -5.3 % | $ 7.48 B | ||
|
Natera
NTRA
|
706 M | $ 186.36 | -5.36 % | $ 18.3 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
11 B | $ 25.23 | -1.06 % | $ 23.9 B | ||
|
Guardant Health
GH
|
-99.3 M | $ 94.92 | -3.79 % | $ 11.9 B | ||
|
Personalis
PSNL
|
261 M | $ 6.36 | -5.22 % | $ 568 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 116.38 | -0.61 % | $ 9.6 B | ||
|
Senseonics Holdings
SENS
|
61 M | $ 5.77 | -0.86 % | $ 241 M | ||
|
Soleno Therapeutics
SLNO
|
450 M | $ 53.01 | 0.04 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
4.1 M | $ 2.34 | -2.9 % | $ 5.38 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 250.4 | -1.43 % | $ 20.8 B | ||
|
Thermo Fisher Scientific
TMO
|
110 B | $ 438.34 | -2.2 % | $ 165 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.57 | -1.59 % | $ 205 M | ||
|
Celcuity
CELC
|
101 M | $ 137.68 | 2.2 % | $ 6.44 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 49.17 | -7.14 % | $ 2.94 B | ||
|
Neogen Corporation
NEOG
|
2.07 B | $ 8.19 | -2.85 % | $ 1.78 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 186.61 | -0.71 % | $ 20.7 B | ||
|
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M |